Product Analyst II - Remote US

It’s More Than a Career, It’s a Mission. Our people are the foundation of our success. By joining our growing team at Sarah Cannon Research Institute (SCRI), a subsidiary of McKesson, you will have the opportunity to become part of one of the largest community-based cancer programs to advance oncology treatments and improve outcomes for cancer patients across the globe. We look for mission-driven candidates who have a desire to advance the fight against cancer and make a difference in the lives of patients diagnosed with cancer every day.

Our Mission People who live with cancer – those who work to prevent it, fight it, and survive it – are at the heart of every decision we make. Bringing the most innovative medical minds together with the most passionate caregivers in their communities, we are transforming care and personalizing treatment. Through clinical excellence and cutting-edge research, SCRI is redefining cancer care around the world.

The Product Analyst II – Digital Transformation advances SCRI’s digital strategy by translating business needs into practical technology solutions. Serving as a bridge between business and IT teams, this role supports process improvement, data integrity, and AI-enabled transformation within SCRI Development Innovations. The position emphasizes hands-on delivery, rapid experimentation, and measurable business outcomes.

This is a remote position based in the US: relocation assistance and visa sponsorship are not available. Duties & Responsibilities

• Partner with business and IT teams to define requirements and lead initiatives from problem discovery through pilot delivery.
• Identify AI and automation opportunities and develop, test, and refine prototypes and solutions.
• Translate business needs into user stories, workflows, and specifications; support backlog refinement, release planning, and UAT.
• Ensure solutions align with data, integration, 21 CFR Part 11, and responsible AI requirements.
• Support change management, documentation, user adoption, and reusable digital/AI solutions.

Knowledge & Skills

• Knowledge of Agile, SDLC, data governance, interoperability, and regulatory requirements within clinical research.
• Familiarity with AI agents, automation tools, APIs, coding concepts, and cloud platforms such as AWS and Azure.
• Experience with research technologies such as Veeva, Medidata, or Oracle.
• Proficiency with Microsoft Copilot and tools such as Jira, Confluence, Planview, or Smartsheet.
• Strong analytical, problem-solving, communication, requirements, and stakeholder management skills.
• Ability to build and evaluate AI-enabled or low/no-code proofs of concept and assess business value and ROI.

Abilities

• Translate digital and AI strategy into executable solutions and measurable results.
• Collaborate effectively with leaders, product owners, business stakeholders, and delivery teams.
• Rapidly prototype, test, and iterate solutions based on user and system feedback.
• Manage competing priorities and adapt in a fast-paced, innovative environment.
• Demonstrate a commitment to continuous learning, quality, and SCRI’s mission.

Minimum Qualifications

• 3–5+ years of product or business analysis experience in digital transformation environments.
• Experience supporting healthcare or life sciences technology/product initiatives.
• Demonstrated success driving technology adoption and identifying high-value AI or automation opportunities.
• Hands-on experience developing or piloting low/no-code, AI-enabled, or other proof-of-concept solutions.
• Strong analytical skills with experience communicating progress, ROI, and outcomes to leadership.

About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together more than 1,300 physicians who are enrolling patients into clinical trials at more than 200 locations in 20+ …